15hon MSN
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...
Key Takeaways Shares of Hims & Hers Health touched a fresh record high in Wednesday trading after the company announced its ...
Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...
Shares of Hims & Hers (NYSE: HIMS) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the ...
BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...
What Hims & Hers stock could be witnessing now is a short-squeeze. As its stock began rising sharply, short-sellers move to get out. So over the past week, we’ve seen shares surge 60%. In midday ...
Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $36.43, ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback